000182638 001__ 182638
000182638 005__ 20240229145726.0
000182638 0247_ $$2doi$$a10.1182/blood.2022016943
000182638 0247_ $$2pmid$$apmid:36375119
000182638 0247_ $$2ISSN$$a0006-4971
000182638 0247_ $$2ISSN$$a1528-0020
000182638 0247_ $$2altmetric$$aaltmetric:138419281
000182638 037__ $$aDKFZ-2022-02815
000182638 041__ $$aEnglish
000182638 082__ $$a610
000182638 1001_ $$00000-0002-3838-8763$$aDelage, Lorric$$b0
000182638 245__ $$aBTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1.
000182638 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2023
000182638 3367_ $$2DRIVER$$aarticle
000182638 3367_ $$2DataCite$$aOutput Types/Journal article
000182638 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1678806584_8936
000182638 3367_ $$2BibTeX$$aARTICLE
000182638 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182638 3367_ $$00$$2EndNote$$aJournal Article
000182638 500__ $$a2023 Mar 9;141(10):1209-1220
000182638 520__ $$aUnderstanding the functional role of mutated genes in cancer is required to translate the findings of cancer genomics into therapeutic improvement. BTG1 is recurrently mutated in the MCD/C5 subtype of diffuse large B cell lymphoma (DLBCL), which is associated with extranodal dissemination. There, we provide evidence that Btg1 knock-out accelerates the development of a lethal lymphoproliferative disease driven by Bcl2 overexpression. We further show that the scaffolding protein BCAR1 is a BTG1 partner. Furthermore, following BTG1 deletion or expression of BTG1 mutations observed in DLBCL patients, the overactivation of the BCAR1-RAC1 pathway confers increased migration ability in vitro and in vivo. These modifications are targetable with the SRC inhibitor dasatinib, which opens novel therapeutic opportunities in BTG1 mutated DLBCL.
000182638 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000182638 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182638 7001_ $$aLambert, Mireille$$b1
000182638 7001_ $$aBardel, Emilie$$b2
000182638 7001_ $$00000-0001-9398-7200$$aKundlacz, Cindy$$b3
000182638 7001_ $$aChartoire, Dimitri$$b4
000182638 7001_ $$aConchon, Axel$$b5
000182638 7001_ $$aPeugnet, Anne-Laure$$b6
000182638 7001_ $$aGorka, Lucas$$b7
000182638 7001_ $$00000-0002-2481-8275$$aAuberger, Patrick$$b8
000182638 7001_ $$aJacquel, Arnaud$$b9
000182638 7001_ $$aSoussain, Carole$$b10
000182638 7001_ $$aDestaing, Olivier$$b11
000182638 7001_ $$0P:(DE-He78)25d3c74b949988c637571e696fc04b25$$aDelecluse, Henri-Jacques$$b12$$udkfz
000182638 7001_ $$0P:(DE-He78)3877ae274d0271d6bf311bb46539f013$$aDelecluse, Susanne$$b13$$udkfz
000182638 7001_ $$00000-0001-7629-703X$$aMerabet, Samir$$b14
000182638 7001_ $$aTraverse-Glehen, Alexandra$$b15
000182638 7001_ $$00000-0002-9541-8666$$aSalles, Gilles A$$b16
000182638 7001_ $$00000-0003-2694-7510$$aBachy, Emmanuel$$b17
000182638 7001_ $$aBillaud, Marc$$b18
000182638 7001_ $$aGhesquieres, Herve$$b19
000182638 7001_ $$aGenestier, Laurent$$b20
000182638 7001_ $$aRouault, Jean Pierre$$b21
000182638 7001_ $$aSujobert, Pierre$$b22
000182638 773__ $$0PERI:(DE-600)1468538-3$$a10.1182/blood.2022016943$$gp. blood.2022016943$$n10$$p1209-1220$$tBlood$$v141$$x0006-4971$$y2023
000182638 909CO $$ooai:inrepo02.dkfz.de:182638$$pVDB
000182638 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)25d3c74b949988c637571e696fc04b25$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000182638 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3877ae274d0271d6bf311bb46539f013$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000182638 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000182638 9141_ $$y2022
000182638 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000182638 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000182638 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000182638 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD : 2022$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000182638 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bBLOOD : 2022$$d2023-10-21
000182638 9201_ $$0I:(DE-He78)F100-20160331$$kF100$$lF100 Pathologie infektionsbedingter Tumoren$$x0
000182638 980__ $$ajournal
000182638 980__ $$aVDB
000182638 980__ $$aI:(DE-He78)F100-20160331
000182638 980__ $$aUNRESTRICTED